ReviewDiabetes, obesity & metabolism2026
Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.
Review in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.Obesity pillars · 2026Article
- Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment effects and optimal strategies for treatment withdrawal. Recent systematic reviews and meta-analyses consistently demonstrate that weight regain after GLP-1RA discontinuation is substantial and follows a characteristic trajectory, with a large proportion occurring during the early post-cessation period. This front-loaded pattern suggests that the initial months after treatment cessation represent a critical window influencing long-term outcomes. Mechanistically, post-cessation weight regain appears to reflect the interaction of multiple processes. These include restoration of appetite following withdrawal of pharmacological GLP-1 signalling, compensatory increases in orexigenic hormones such as ghrelin, alterations in incretin balance including glucose-dependent insulinotropic polypeptide (GIP) and potential adaptive changes in GLP-1 receptor signalling pathways during prolonged pharmacological exposure, although evidence for a direct role in post-cessation weight regain remains limited. These converging mechanisms have important clinical implications, as abrupt discontinuation may result in a transient mismatch between increased biological drive for weight regain and the sudden loss of pharmacological appetite suppression. In this context, strategies aimed at mitigating early weight regain are of increasing interest. Recent randomised evidence suggests that reduced-intensity pharmacological maintenance may attenuate weight regain compared with abrupt discontinuation. However, whether structured tapering strategies can successfully facilitate treatment discontinuation remains unknown and requires prospective evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.